VERAXA Biotech's Smart Cancer Therapies Gain Momentum

LOS ANGELES, CA - June 17, 2026 - VERAXA Biotech (NASDAQ: VRXA) is making waves in the oncology space with a diversified pipeline that includes monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and its proprietary BiTAC-based therapeutic formats. The company, as highlighted in a recent article, is dedicated to discovering and developing next-generation antibody-based therapeutics for solid tumors, aiming to deliver smart cancer therapies with curative potential and improved safety profiles. VERAXA's vision centers on dual-targeting ADCs and T-cell engagers (TCEs) built on its patented BiTAC concept, which enhances precision, safety, and effectiveness. By focusing on conditionally active ADC and TCE platforms, VERAXA is positioning itself within two rapidly growing segments of the global oncology market.

Founded on scientific breakthroughs at the European Molecular Biology Laboratory, VERAXA is advancing its pipeline of ADCs and BiTAC formats into clinical development. The company's suite of transformative technologies and quality-by-design principles drive its progress. For more details, the full article is available at https://ibn.fm/9jQnN. Regular updates can be found at www.VERAXA.com. The newsroom at https://ibn.fm/VRXA provides the latest news and updates on VRXA. This information is distributed by InvestorBrandNetwork (IBN) via NEWMEDIAWIRE, with disclaimers available on the IBN website.

VERAXA's approach is particularly compelling as it targets solid tumors with potentially first-in-class therapies. The BiTAC concept represents a novel mechanism to improve treatment outcomes, addressing the need for more effective and safer cancer treatments. As the company progresses, it could significantly impact the oncology landscape, offering new hope for patients. However, forward-looking statements involve risks, as outlined in SEC filings, and investors should consider these factors. View the original release on www.newmediawire.com.